SPRO — Spero Therapeutics Inc

Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ. It is led by Esther P. Rajavelu, based in 675 Massachusetts Avenue, Cambridge, MA, United States, 02139, with about 25 employees. Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Latest reported SPRO revenue for 2025-09-30 was $5.4M. Net income was -$7.4M. Revenue was down 61.6% from 2025-06-30 to 2025-09-30. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.

On the latest cached filing, SPRO: SECURITIES AND EXCHANGE COMMISSION (8-K 2026-08-28). This SPRO stock page is the analysis view: what changed in the numbers, and why it matters for Spero Therapeutics Inc.

Use this SPRO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SPRO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SPRO SEC filings page. Lician reads the product cache first so this HTML stays unique to Spero Therapeutics Inc even when a live quote feed is slow.